explore -WSS

explore

author：leisure time 2025-10-01 06:01:09 - browse：5

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

explore

leisure time

WSS

Cancer, immunology, HIV research ensnared in fetal tissue politics

Ohio still needs to do more to protect the right to abortion

First transplant of an entire human eye performed

Medical devices makers are asking for forgiveness, not permission

CVS, Rite Aid closures threaten to worsen pharmacy deserts

NIH chief: government has fallen behind pharma on clinical trials

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cancer, immunology, HIV research ensnared in fetal tissue politics

Cancer drug shortages should be causing more outrage

What Kate Middleton's cancer revelation might teach the world

Medical records are filled with copy

Type 2 diabetes prevention programs work at large scale: study

What does generative AI mean for health care? We asked experts

Surgeons perform first xenotransplant using CRISPR'd pig kidney

DIEP, the 'gold standard' of breast reconstruction, is under threat

Bring on the sabbaticals for nurses

hotspot

This gene therapy has record $4.25 million price. It's saved children.

Diabetes management: Digital health tools fall short, study says

6 surprising facts about sugar

Publishing genetic code of viruses could cause disaster

Bring on the sabbaticals for nurses

Asbestos ban is immediate, but health effects will linger for decades

explore

focus

leisure time

focus